Transmitted drug resistance mutations in antiretroviral-naïve injection drug users with chronic HIV-1 infection in Iran

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Memarnejadian, Arash ^a,f   Menbari, Shahoo ^b   Mansouri, Seyed Ali ^c   Sadeghi, Leila ^d   Vahabpour, Rouhollah ^e   Aghasadeghi, Mohammad Reza ^a   Mostafavi, Ehsan ^a   Abdi, Mohammad ^b  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; HEPATITIS B ANTIGEN; HEPATITIS C ANTIBODY; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALGORITHM; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEVELOPING COUNTRY; DISEASE DURATION; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; DIVORCED PARENT; FAMILY SIZE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INTRAVENOUS DRUG ABUSE; IRAN; MALE; MARRIED PERSON; NUCLEOTIDE SEQUENCE; PHYLOGENY; SEROCONVERSION; VIRUS GENOME; VIRUS MUTATION; VIRUS STRAIN; DRUG EFFECTS; DRUG USE; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROBIAL SENSITIVITY TEST; MUTATION; RISK FACTOR; TRANSMISSION; VIROLOGY; VIRUS GENE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; DRUG USERS; FEMALE; GENES, VIRAL; GENOTYPE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IRAN; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; PHYLOGENY; RISK FACTORS;

EID: 84930654771     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126955     Document Type: Article

References (32)

1. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60. Epub 1998/03/27. doi: 10.1056/NEJM199803263381301 PMID: 9516219.
2. Bakhouch K, Oulad-Lahcen A, Bensghir R, Blaghen M, Elfilali KM, Ezzikouri S, et al. The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naive (HIV1)-infected individuals in Casablanca, Morocco. J Infect Dev Ctries. 2009; 3(5):380-91. Epub 2009/09/18. PMID: 19759509.
3. Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005; 40(3):468-74. Epub 2005/01/26. CID33817 [pii] doi: 10.1086/427212 PMID: 15668873.
4. Re MC, Monari P, Bon I, Borderi M, Chiodo F. Conflicting interpretations of the prevalence of mutations associated with drug resistance in antiviral naive HIV-1 patients with acute and chronic infection. Int J Antimicrob Agents. 2004; 23(2):164-8. Epub 2004/03/12. doi: 10.1016/j.ijantimicag.2003.06.005S0924857903003704 [pii]. PMID: 15013042.
5. Re MC, Monari P, Bon I, Gibellini D, Vitone F, Borderi M, et al. Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patients. BMC Microbiol. 2001; 1:30. Epub 2001/12/12. PMID: 11737863; PubMed Central PMCID: PMC60646.
6. Sullivan PS, Buskin SE, Turner JH, Cheingsong R, Saekhou A, Kalish ML, et al. Low prevalence of antiretroviral resistance among persons recently infected with human immunodeficiency virus in two US cities. Int J STD AIDS. 2002; 13(8):554-8. Epub 2002/08/27. doi: 10.1258/095646202760159684 PMID: 12194739.
7. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005; 192(6):958-66. Epub 2005/08/19. JID34030 [pii] doi: 10.1086/432916 PMID: 16107947.
8. Manosuthi W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. HIV-1 drug resistance-associated mutations among antiretroviral-naive Thai patients with chronic HIV-1 infection. J Med Virol. 2013; 85(2):194-9. Epub 2012/11/20. doi: 10.1002/jmv.23452 PMID: 23161095.
9. Toni T, Masquelier B, Minga A, Anglaret X, Danel C, Coulibaly A, et al. HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Cote d'Ivoire: A 4-year survey, 2002-2006. AIDS Res Hum Retroviruses. 2007; 23(9):1155-60. Epub 2007/10/09. doi: 10.1089/aid.2007.0072 PMID: 17919113.
10. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008; 13 Suppl 2:1-13. Epub 2008/06/26. PMID: 18578063.
11. Adolescents PoAGfAa. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.: Department of Health and Human Services; 2014.
12. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012; 308(4):387-402. Epub 2012/07/24. 1221704 [pii] doi: 10.1001/jama.2012.7961 PMID: 22820792.
13. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, de Luca A, Palmisano L, Paraskevis D, et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev. 2011; 13(2):77-108. Epub 2011/05/19. PMID: 21587341.
14. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008; 13 Suppl 2:25-36. Epub 2008/06/26. PMID: 18575189.
15. National AIDS Committee Secretariat MoHaME. Islamic Re-public of Iran AIDS Progress Report On Monitoring of the United Nations General Assembly Special Session (UNGASS) on HIV and AIDS. March 2014. Report No.
16. Khajehkazemi R, Osooli M, Sajadi L, Karamouzian M, Sedaghat A, Fahimfar N, et al. HIV prevalence and risk behaviours among people who inject drugs in Iran: the 2010 National Surveillance Survey. Sex Transm Infect. 2013. doi: 10.1136/sextrans-2013-051204
17. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009; 4(3):e4724. Epub 2009/03/07. doi: 10.1371/journal.pone.0004724 PMID: 19266092; PubMed Central PMCID: PMC2648874.
18. Jahanbakhsh F, Hattori J, Matsuda M, Ibe S, Monavari SH, Memarnejadian A, et al. Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011. PLoS One. 2013; 8(4):e61864. Epub 2013/04/30. doi: 10.1371/journal.pone.0061864 PONE-D-12-40726 [pii]. PMID: 23626742; PubMed Central PMCID: PMC3633940.
19. Mousavi SM, Hamkar R, Gouya MM, Safaie A, Zahraei SM, Yazdani Z, et al. Surveillance of HIV drug resistance transmission in Iran: experience gained from a pilot study. Arch Virol. 2010; 155(3):329-34. Epub 2010/01/07. doi: 10.1007/s00705-009-0583-6 PMID: 20052598.
20. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003; 31(1):298-303. Epub 2003/01/10. PMID: 12520007; PubMed Central PMCID: PMC165547.
21. Baesi K, Ravanshad M, Ghanbarisafari M, Saberfar E, Seyedalinaghi S, Volk JE. Antiretroviral drug resistance among antiretroviral-naive and treatment experienced patients infected with HIV in Iran. J Med Virol. 2014; 86(7):1093-8. Epub 2014/04/18. doi: 10.1002/jmv.23898 PMID: 24740443.
22. Sugiura W, Matsuda M, Abumi H, Yamada K, Taki M, Ishikawa M, et al. Prevalence of drug resistance-related mutations among HIV-1s in Japan. Jpn J Infect Dis. 1999; 52(1):21-2. Epub 2000/05/16. PMID: 10808258.
23. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011; 28(10):2731-9. Epub 2011/05/07. msr121 [pii] doi: 10.1093/molbev/msr121 PMID: 21546353; PubMed Central PMCID: PMC3203626.
24. Pineda-Pena AC, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol. 2013; 19:337-48. Epub 2013/05/11. S1567-1348(13)00181-0 [pii] doi: 10.1016/j.meegid.2013.04.032 PMID: 23660484.
25. Hamkar R, Mohraz M, Lorestani S, Aghakhani A, Truong HH, McFarland W, et al. Assessing subtype and drug-resistance-associated mutations among antiretroviral-treated HIV-infected patients. AIDS. 2010; 24 Suppl 2:S85-91. Epub 2010/07/17. doi: 10.1097/01.aids.0000386738.32919.67 00002030-201007002-00011 [pii]. PMID: 20610954.
26. Sanders-Buell E, Saad MD, Abed AM, Bose M, Todd CS, Strathdee SA, et al. A nascent HIV type 1 epidemic among injecting drug users in Kabul, Afghanistan is dominated by complex AD recombinant strain, CRF35-AD. AIDS Res Hum Retroviruses. 2007; 23(6):834-9. Epub 2007/07/03. doi: 10.1089/aid.2006.0299 PMID: 17604548.
27. Mumtaz G, Hilmi N, Akala FA, Semini I, Riedner G, Wilson D, et al. HIV-1 molecular epidemiology evidence and transmission patterns in the Middle East and North Africa. Sex Transm Infect. 2011; 87 (2):101-6. Epub 2010/11/03. sti.2010.043711 [pii] doi: 10.1136/sti.2010.043711 PMID: 21036790.
28. Shah S, Xing H, Altaf A, Chen B, Liao L, Jia Y, et al. Antiretroviral drug resistance mutations among treated and treatment-naive patients in Pakistan: diversity of the HIV type 1 pol gene in Pakistan. AIDS Res Hum Retroviruses. 2011; 27(12):1277-82. Epub 2011/05/20. doi: 10.1089/AID.2010.0324 PMID: 21591988; PubMed Central PMCID: PMC3227241.
29. Liu L, May S, Richman DD, Hecht FM, Markowitz M, Daar ES, et al. Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance. AIDS. 2008; 22(7):835-9. Epub 2008/04/23. doi: 10.1097/QAD.0b013e3282f5ff71 00002030-200804230-00005 [pii]. PMID: 18427201; PubMed Central PMCID: PMC2716722.
30. Perno CF, Cozzi-Lepri A, Balotta C, Bertoli A, Violin M, Monno L, et al. Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation. AIDS. 2002; 16 (4):619-24. Epub 2002/03/02. PMID: 11873006.
31. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS. 2000; 14(2):F17-23. Epub 2000/03/09. PMID: 10708278.
32. Kiertiburanakul S, Chaiwarith R, Sirivichayakul S, Ditangco R, Jiamsakul A, Li PC, et al. Comparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian Patients. PLoS One. 2013; 8(6):e62057. Epub 2013/07/05. doi: 10.1371/journal.pone.0062057 PONE-D-12-35130 [pii]. PMID: 23826076; PubMed Central PMCID: PMC3694952.